Clinical Trial Search

Primary: Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection on Day 8 — 35; 38 Participants — p=0.407

Primary: Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period) — -0.56; 0.07 Percent — p=<0.0001

Primary: Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP) — 157.873; 158.236; 158.594; -22.483 mm Hg — p=0.184

Primary: The Percentage of Patients With at Least 75% Reduction in Psoriasis Area and Severity Index (PASI 75) Response at Week 16 — 68.2; 70.4 Percentage (%)

Primary: Mean Time From Start Administration of Sugammadex to Recovery of Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 — 1.45; 1.32 minutes

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) After 16 Weeks of Treatment in Rosiglitazone Group and Placebo Group — -0.62; 0.19 Percentage of Glycosylated…

Primary: MCP-1:Creatinine Ratio in Urine — 27.9; 24.3 ng/mmol

Primary: Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment — 0.52; 0.41 events — p=0.194

Primary: Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients — -0.005; -0.005; -0.007; -0.005 10^9 cells/L

Primary: Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16 — 100; 100 percentage of participants

Primary: Overall Survival (OS) — 23.82; 22.21 months — p== 0.5236

Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) — -12.4; -14.8; -14.1 score on a scale — p=0.0417

Primary: Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 — -17.0; -15.4 Lesions — p=0.2301

Primary: Long-Term Safety Assessed Through Adverse Events and Local Skin Reactions — 197; 124; 18; 402 Participants

Primary: Percentage of Participants With a Failed Voiding Trial — 35; 32; 9; 12 Participants